Skip to content

Norwegian Microemboli in Acute Stroke Study

Norwegian Microemboli in Acute Stroke Study (NOR-MASS)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03543319
Acronym
NOR-MASS
Enrollment
400
Registered
2018-06-01
Start date
2018-06-12
Completion date
2020-12-31
Last updated
2019-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embolic Stroke, Ischemic Stroke, Microemboli

Brief summary

BACKGROUND: The cause of ischemic stroke remains undetermined in 30-40% of the cases, but circulating blood clots (thromboemboli) are a postulated common denominator in approx. 75% of patients. Transcranial Doppler monitoring (TCDM) is a non-invasive method of detecting circulating microemboli (CME) in the human cerebral circulation. The method is not used systematically in unselected groups of patients with repeated long-term registrations. New ultrasound equipment is ambulatory, less unpleasant for the patient and allows extended monitoring sessions. This may vastly simplify the implementation of TCDM as a clinically useful diagnostic tool. AIMS: Determine the usefulness of TCDM in acute stroke diagnostics by assessing prevalence and frequency of CME in unselected patients with ischemic stroke, the influence of antithrombotic drugs on CME and the relationship between MES and recurrent stroke or transient ischemic attack (TIA). HYPOTHESES: Prevalence and frequency of CME are higher during the first 24 hours than at later follow-up. Stroke etiology can be assessed by the presence or absence of CME. Presence of CME is associated with increased risk of recurrent TIA of stroke within 3 months and 1 year. Cessation of CME after the start of antithrombotic treatment is associated with reduced risk of recurrent TIA or stroke.

Detailed description

* Standardized questionnaire * Clinical work-up in accordance with hospital standard operating procedures, i.e. radiological and cardiological procedures, neurovascular ultrasound, clinical scoring, etc. * 1st Transcranial Doppler monitoring (TCDM) at admission if within 24 hours after stroke onset (day 1). TCDM is repeated at 18-36 hours and at day 3. Microembolic signals are automatically registered by the software and subsequently verified manually.

Interventions

None listed

Sponsors

University of Bergen
CollaboratorOTHER
Haukeland University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Admitted to hospital \< 24 hours after onset of ischemic stroke

Exclusion criteria

* Temporal bone window inadequate for transcranial Doppler examination * Participation in ongoing sonothrombolysis study (NOR-SASS 2) * Reduced ability to cooperate * No informed consent can be obtained

Design outcomes

Primary

MeasureTime frame
Prevalence of circulating microemboliUp to 24 hours after symptom onset

Secondary

MeasureTime frame
Prevalence of circulating microemboli as a function of time and antithrombotic drugs3 days after symptom onset
Prevalence of MRI DWI lesions18-36 hours after symptom onset
Recurrence of ischemic stroke/TIA3 months

Countries

Norway

Contacts

Primary ContactSander Aarli, MD
drar@helse-bergen.no+4799557918
Backup ContactAnnette Fromm, MD, PhD
atfm@helse-bergen.no

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026